Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulant thrombins.

E Di Cera1

  • 1Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri, USA.

Trends in Cardiovascular Medicine
|February 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual effect of histone H4 on prothrombin activation.

Journal of thrombosis and haemostasis : JTH·2016
Same author

WEDGE: an anticoagulant thrombin mutant produced by autoactivation.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Na+ binding to meizothrombin desF1.

Cellular and molecular life sciences : CMLS·2008
Same author

Role of the A chain in thrombin function.

Cellular and molecular life sciences : CMLS·2008
Same author

Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.

Journal of thrombosis and haemostasis : JTH·2008
Same author

Serine peptidases: classification, structure and function.

Cellular and molecular life sciences : CMLS·2008
Same journal

Inflammation as a Fulcrum in Cardiovascular Disease: The Evolving Case for High-Sensitivity C-Reactive Protein.

Trends in cardiovascular medicine·2026
Same journal

Comment on "advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation".

Trends in cardiovascular medicine·2026
Same journal

Response to: Comment on "Advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation" (TCM-D-26-00198).

Trends in cardiovascular medicine·2026
Same journal

High-sensitivity C-reactive protein as a prognostic biomarker in cardiovascular diseases: implications for atherosclerosis, chronic kidney disease, and heart failure - a review.

Trends in cardiovascular medicine·2026
Same journal

The cost of false dichotomies in a dynamic disease.

Trends in cardiovascular medicine·2026
Same journal

Late-presenting ST-segment elevation myocardial infarction: is it just a matter of time? From temporal cutoffs to biological staging.

Trends in cardiovascular medicine·2026
See all related articles

Researchers engineered thrombin enzymes, altering the sodium (Na+) binding site to remove anticoagulant activity while preserving procoagulant function. This discovery offers new therapeutic avenues and insights into blood coagulation regulation.

Area of Science:

  • Biochemistry
  • Hematology
  • Enzyme Engineering

Background:

  • Thrombin, a key enzyme in blood coagulation, exhibits both procoagulant and anticoagulant functions.
  • The allosteric binding of sodium ions (Na+) near thrombin's active site modulates its enzymatic activity.
  • Understanding thrombin's structure-function relationship is crucial for developing targeted anticoagulant therapies.

Purpose of the Study:

  • To investigate the role of the Na+ binding site in modulating thrombin's dual procoagulant and anticoagulant activities.
  • To engineer recombinant thrombins with selectively altered anticoagulant properties.
  • To explore the therapeutic potential of modified thrombins and their implications for coagulation factor regulation.

Main Methods:

  • Site-directed mutagenesis was employed to introduce substitutions in or around the Na+ binding site of thrombin.

Related Experiment Videos

  • Biochemical assays were performed to assess the procoagulant and anticoagulant activities of engineered thrombins.
  • Analysis of structure-function relationships was conducted based on the observed enzymatic properties.

    • Main Results:

    • Engineered recombinant thrombins with mutations in the Na+ binding site demonstrated a significant loss of anticoagulant activity.
    • These modified thrombins retained substantial procoagulant function, indicating selective modulation of activity.
    • The findings highlight the critical role of Na+ in regulating thrombin's anticoagulant function.

    Conclusions:

    • Selective engineering of thrombin's Na+ binding site can decouple its procoagulant and anticoagulant activities.
    • Engineered anticoagulant-deficient thrombins represent a promising alternative for anticoagulant therapies.
    • This research enhances the understanding of sodium's role as a coagulation factor and the regulation of vitamin K-dependent enzymes.